NCT02611258View on ClinicalTrials.gov

Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 31, 2021

Study Completion Date

June 30, 2021

Conditions
Cushing's Syndrome Cardiomyopathy
Interventions
DRUG

Tadalafil

Tadalafil 20 mg to be taken orally once daily, for 3 months

Trial Locations (1)

00161

Elisa Giannetta, Rome

All Listed Sponsors
lead

Andrea M. Isidori

OTHER

NCT02611258 - Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs | Biotech Hunter | Biotech Hunter